No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.

Review of recent advances in biomimetic drug delivery for rheumatoid arthritis, highlighting targeted nanomedicine strategies ...

Use of disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis ...

This study analyzes 20 years of data from the Food and Drug Administration’s Adverse Event Reporting System (FAERS) to reveal ...

A new nanoparticle drug has shown preclinical promise in both preventing rheumatoid arthritis and reducing painful flare-ups, offering hope for a targeted, steroid-sparing treatment that calms the ...

Patients who require biologic disease-modifying antirheumatic drugs (DMARDs) for severe RA are less likely to achieve sustained DMARD-free remission than those not needing the medication. Patients ...

Paternal exposure to methotrexate before conception is not linked to increased risks for adverse birth outcomes, but exposures to some other immunosuppressants and biologics do carry risks.

Concomitant inflammatory bowel disease (IBD) negatively affects disease control and treatment response among patients with psoriatic arthritis (PsA) receiving biologic therapy, according to study ...

Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who cycled JAK inhibitors after inadequate response had a 38.7% remission ...